Matches in Wikidata for { <http://www.wikidata.org/entity/Q93116681> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q93116681 description "article scientifique publié en 2019" @default.
- Q93116681 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q93116681 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q93116681 description "scientific article published on 01 October 2019" @default.
- Q93116681 description "wetenschappelijk artikel" @default.
- Q93116681 description "наукова стаття, опублікована 1 жовтня 2019" @default.
- Q93116681 name "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 name "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 type Item @default.
- Q93116681 label "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 label "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 prefLabel "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 prefLabel "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 P1433 Q93116681-21D09CE2-20AC-472D-A4D2-6EABBA0D5DD9 @default.
- Q93116681 P1476 Q93116681-BC4DEA3E-FA27-4D8C-8CB1-BF2C5F007EE5 @default.
- Q93116681 P2093 Q93116681-0A0D9447-BFBA-489F-9EFF-F5CF78D1EBA1 @default.
- Q93116681 P2093 Q93116681-0FBE69FF-93D8-4131-9969-ABF858764E4A @default.
- Q93116681 P2093 Q93116681-2E1A3707-1022-4141-8ED0-E78A05BCD57F @default.
- Q93116681 P2093 Q93116681-31C83663-E820-41DE-8378-3572DB4AFA55 @default.
- Q93116681 P2093 Q93116681-4AA75E02-8620-4B30-BFE4-E2C376A18112 @default.
- Q93116681 P2093 Q93116681-4FFDC5C3-62B5-47A6-BFFD-C8C9B8CF8388 @default.
- Q93116681 P2093 Q93116681-53FC208C-8A0F-4A78-B586-9F1174FCE1CF @default.
- Q93116681 P2093 Q93116681-84EBF0E0-399F-4A76-ADA0-A1188F1D1EE3 @default.
- Q93116681 P2093 Q93116681-865A771C-9EC4-4C31-8AE7-9A4CED3F90BA @default.
- Q93116681 P2093 Q93116681-9B0901B7-34B0-4B08-9018-41432CF3FD68 @default.
- Q93116681 P2093 Q93116681-A61D0624-6829-44E5-9D2D-7D8712C8CC25 @default.
- Q93116681 P2093 Q93116681-B4B22AD5-8C74-4C97-8EDD-737E8F70EB1F @default.
- Q93116681 P2093 Q93116681-BE241607-C09F-41E2-9D3A-6BF6F306117C @default.
- Q93116681 P2093 Q93116681-BEB040A7-E10C-4FFD-AEF6-2BE8795448BF @default.
- Q93116681 P2093 Q93116681-CB90EFB2-582C-4BF3-98BC-F6D0B8D74E98 @default.
- Q93116681 P2093 Q93116681-D264D81F-95E5-49D8-8940-ACBAE7810C81 @default.
- Q93116681 P2093 Q93116681-D4E2E2F4-B23B-4453-BB73-923347E990C0 @default.
- Q93116681 P2093 Q93116681-DF85E9EC-EA61-4A88-977A-141F006FC2E5 @default.
- Q93116681 P2093 Q93116681-E65F8A18-45BC-4024-BE34-52BCB32EEA5F @default.
- Q93116681 P2093 Q93116681-EAA92E25-06AC-46C2-8F23-F4C5EEF8871A @default.
- Q93116681 P304 Q93116681-5B5C03BB-437A-4B13-9A33-DCF002799C51 @default.
- Q93116681 P31 Q93116681-DB94E8CF-134F-4146-9A6C-32A7CE4202DC @default.
- Q93116681 P356 Q93116681-11072C3D-5EF7-4ED9-BB7A-1CA25E108D86 @default.
- Q93116681 P433 Q93116681-7B76FEEA-F995-45DC-975B-F6DDCDB43B26 @default.
- Q93116681 P478 Q93116681-1A095DA6-D2ED-4E53-9A13-B788552C1CB8 @default.
- Q93116681 P50 Q93116681-2134C42A-6748-4007-8D6B-3D4A4201FA67 @default.
- Q93116681 P577 Q93116681-87571509-2F5B-4DF0-B7EE-FA65E2AEE3AF @default.
- Q93116681 P698 Q93116681-29D9A618-F3B5-42F6-8B7E-8A808DCA8256 @default.
- Q93116681 P921 Q93116681-4B996EFB-DDA9-42EF-8F95-49061E9A4200 @default.
- Q93116681 P921 Q93116681-D3F73024-A948-4BA5-93B4-B0C3EC4A6818 @default.
- Q93116681 P356 JJZ071 @default.
- Q93116681 P698 30989180 @default.
- Q93116681 P1433 Q15817379 @default.
- Q93116681 P1476 "Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study" @default.
- Q93116681 P2093 "D Branquinho" @default.
- Q93116681 P2093 "F Cornillie" @default.
- Q93116681 P2093 "F Magro" @default.
- Q93116681 P2093 "F Portela" @default.
- Q93116681 P2093 "H T Sousa" @default.
- Q93116681 P2093 "I Redondo" @default.
- Q93116681 P2093 "J Afonso" @default.
- Q93116681 P2093 "J Lopes" @default.
- Q93116681 P2093 "J Ramos" @default.
- Q93116681 P2093 "L Correia" @default.
- Q93116681 P2093 "M Cravo" @default.
- Q93116681 P2093 "M Patita" @default.
- Q93116681 P2093 "M Silva" @default.
- Q93116681 P2093 "P Caldeira" @default.
- Q93116681 P2093 "P Lago" @default.
- Q93116681 P2093 "P Machado" @default.
- Q93116681 P2093 "Portuguese IBD Group [GEDII]" @default.
- Q93116681 P2093 "R Coelho" @default.
- Q93116681 P2093 "S Fernandes" @default.
- Q93116681 P2093 "S Lopes" @default.
- Q93116681 P304 "1387-1393" @default.
- Q93116681 P31 Q13442814 @default.
- Q93116681 P356 "10.1093/ECCO-JCC/JJZ071" @default.
- Q93116681 P433 "11" @default.
- Q93116681 P478 "13" @default.
- Q93116681 P50 Q40479058 @default.
- Q93116681 P577 "2019-10-01T00:00:00Z" @default.
- Q93116681 P698 "30989180" @default.
- Q93116681 P921 Q323936 @default.
- Q93116681 P921 Q725307 @default.